The Gastrointestinal (GI) Division specializes in the development, manufacturing, and distribution of pharmaceutical products designed to support digestive health and manage gastrointestinal disorders. Backed by stringent quality standards, GMP-certified manufacturing facilities, and compliance with DRAP regulations and the Drug Licensing Management (DML) Rules 2019, the division ensures that all products meet the highest standards of safety, efficacy, and quality.
Our GI product portfolio includes medications for:
The division's flagship therapies include Proton Pump Inhibitors (PPIs), such as Omeprazole Capsules, which effectively reduce gastric acid secretion and promote healing of ulcerative and inflammatory conditions of the gastrointestinal tract.
By combining advanced manufacturing practices, robust quality assurance systems, and a patient-centric approach, the Gastrointestinal Division continues to contribute to improved digestive healthcare outcomes across Pakistan. Our commitment to excellence ensures that healthcare providers and patients receive trusted pharmaceutical solutions that meet evolving medical needs while maintaining compliance with national and international quality standards.